Avlant Nilsson
Overview
Explore the profile of Avlant Nilsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nilsson A, Meimetis N, Lauffenburger D
NPJ Precis Oncol
. 2025 Feb;
9(1):46.
PMID: 39948231
Cancer is a manifestation of dysfunctional cell states. It emerges from an interplay of intrinsic and extrinsic factors that disrupt cellular dynamics, including genetic and epigenetic alterations, as well as...
2.
Meimetis N, Lauffenburger D, Nilsson A
STAR Protoc
. 2025 Jan;
6(1):103573.
PMID: 39823233
Drugs that target specific proteins often have off-target effects. We present a protocol using artificial neural networks to model cellular transcriptional responses to drugs, aiming to understand their mechanisms of...
3.
Meimetis N, Pullen K, Zhu D, Nilsson A, Hoang T, Magliacane S, et al.
NPJ Syst Biol Appl
. 2024 Dec;
10(1):148.
PMID: 39672816
No abstract available.
4.
Perez C, Garmilla A, Nilsson A, Baghdassarian H, Gordon K, Lima L, et al.
bioRxiv
. 2024 May;
PMID: 38746119
The anti-tumor function of engineered T cells expressing chimeric antigen receptors (CARs) is dependent on signals transduced through intracellular signaling domains (ICDs). Different ICDs are known to drive distinct phenotypes,...
5.
Meimetis N, Lauffenburger D, Nilsson A
iScience
. 2024 Apr;
27(4):109509.
PMID: 38591003
Many diseases emerge from dysregulated cellular signaling, and drugs are often designed to target specific signaling proteins. Off-target effects are, however, common and may ultimately result in failed clinical trials....
6.
Meimetis N, Pullen K, Zhu D, Nilsson A, Hoang T, Magliacane S, et al.
NPJ Syst Biol Appl
. 2024 Jan;
10(1):13.
PMID: 38287079
The development of therapeutics and vaccines for human diseases requires a systematic understanding of human biology. Although animal and in vitro culture models can elucidate some disease mechanisms, they typically...
7.
Gunn B, McNamara R, Wood L, Taylor S, Devadhasan A, Guo W, et al.
Cell Rep
. 2023 Apr;
42(4):112402.
PMID: 37061918
The 2013 Ebola epidemic in Central and West Africa heralded the emergence of wide-spread, highly pathogenic viruses. The successful recombinant vector vaccine against Ebola (rVSVΔG-ZEBOV-GP) will limit future outbreaks, but...
8.
Nilsson A, Peters J, Meimetis N, Bryson B, Lauffenburger D
Nat Commun
. 2022 Jun;
13(1):3069.
PMID: 35654811
Mammalian cells adapt their functional state in response to external signals in form of ligands that bind receptors on the cell-surface. Mechanistically, this involves signal-processing through a complex network of...
9.
Vega P, Nilsson A, Kumar M, Niitsu H, Simmons A, Ro J, et al.
Front Oncol
. 2022 May;
12:878920.
PMID: 35600339
The tumor microenvironment plays a key role in the pathogenesis of colorectal tumors and contains various cell types including epithelial, immune, and mesenchymal cells. Characterization of the interactions between these...
10.
Nilsson A, Haanstra J, Engqvist M, Gerding A, Bakker B, Klingmuller U, et al.
Proc Natl Acad Sci U S A
. 2020 Apr;
117(19):10294-10304.
PMID: 32341162
Many cancer cells consume glutamine at high rates; counterintuitively, they simultaneously excrete glutamate, the first intermediate in glutamine metabolism. Glutamine consumption has been linked to replenishment of tricarboxylic acid cycle...